The ongoing Australian 2017 influenza season was so far characterised by record-high laboratory-confirmed influenza notifications \[[@r1]\], high consultation rates, high hospitalisation and mortality rates, particularly in New South Wales \[[@r2]\], large numbers of institutional outbreaks \[[@r2]\] and media attention. The southern hemisphere influenza vaccine used in Australia for this season was a quadrivalent formulation comprised of an A/Michigan/45/2015 (H1N1)pdm09-like virus, an A/Hong Kong/4801/2014 (H3N2)-like virus, a B/Brisbane/60/2008-like virus (of the B/Victoria/2/87 lineage) and a B/Phuket/3073/2013-like virus (of the B/Yamagata/16/88 lineage) \[[@r3],[@r4]\]. This same vaccine composition is being used in the upcoming northern hemisphere for the 2017/18 influenza season \[[@r5]\]. Here we report interim influenza vaccine effectiveness estimates for 2017 in Australia, using sentinel surveillance data.

Data collection
===============

The Australian Sentinel Practices Research Network (ASPREN) and the Victorian Sentinel Practice Influenza Network (VicSPIN) constitute Australia's two sentinel influenza general practice (GP) networks. VicSPIN operates in the state of Victoria, while ASPREN operates nationally. Both surveillance systems use similar data collection methods \[[@r6],[@r7]\], with the key difference that the VicSPIN surveillance period is limited to weeks 18 to 43 (1 May 1-- 29 October), timed to start roughly 2 weeks after vaccination campaigns in mid-April. Briefly, sentinel GPs submit weekly reports of the number of patients seen with influenza-like illness (ILI), defined as fever/history of fever, cough and fatigue, and the total number of patients. Nose/throat swabs are collected from a subset of patients with demographic data, date of ILI onset, vaccination status (self-reported or medical record) and indications for vaccination, such as belonging to an influenza risk group. Swabs are tested by RT-PCR and positive samples are referred to the World Health Organization (WHO) Collaborating Centre for Reference and Research on Influenza in Melbourne, for antigenic characterisation by haemagglutination inhibition assay (HAI) \[[@r8]\] or focus reduction assay (FRA) \[[@r9]\] and genetic sequencing, as described previously \[[@r6]\]. All data were managed and analysed using R version 3.4.1.

Influenza-like illness activity
===============================

ILI data from ASPREN for 2017 and 2012 to 2016 (averaged) are plotted in [Figure 1A](#f1){ref-type="fig"} and indicate consultation rates were higher in 2017 than in the previous 5 years. For the study period from 1 May 2017 to 24 September 2017, i.e. weeks 18--38, the 262 ASPREN GPs and 88 VicSPIN GPs conducted 493,961 consultations, of which 5,678 (1.1%) met the ILI case definition and swabs were collected from 2,465 (43%) of them. Influenza cases were detected in every week of the study period and peaked in week 34 (21--27 August, n = 235). Percentage of positive samples peaked in week 32 (7--13 August) with 58%.

![Sentinel general practice (GP) surveillance data^a^, (A) ILI consultation rates, (B) laboratory detections of influenza patients by week and type/subtype, Australia, 2 January--24 September 2017](17-00707-f1){#f1}

Virological characteristics
===========================

Virological analyses and vaccine effectiveness estimation were restricted to the period 1 May to 24 September (weeks 18-38). During this period, 2,456 patients were swabbed, but samples from 116 patients were excluded because of missing information on vaccination status, and one with missing influenza status. Among the remaining 2,339 patients, working-age adults comprised the majority (n = 1,604, 69%), 440 (19%) were aged \< 15 years and 297 (13%) were aged ≥ 65 years. Around 37% (477/1,279) of test-negative patients were vaccinated in 2017.

Eighty-eight patients tested positive for A(H1)pdm09, 522 were A(H3), 75 were not yet subtyped, 11 were B/Victoria, 259 were B/Yamagata and 105 were influenza B, but the lineage was not yet determined ([Figure 1B](#f1){ref-type="fig"}). Virus isolation was attempted for samples with a cycle threshold value of 30 or less ([Table 1](#t1){ref-type="table"}). HAI testing indicated that isolates were generally antigenically similar to their respective vaccine strains. Thirty-seven percent (n=98) of A(H3) viruses yielded insufficient haemagglutinin titres for testing by HAI and were instead assessed by FRA. In HAI and FRA, 10% (7/67) and 0% (0/75) of A(H3) viruses, respectively, were low reacting to post-infection ferret antisera raised to cell-propagated A/Hong Kong/4801/2014-like viruses. However, these proportions increased to 33% (22/67) and 20% (15/75), respectively, when tested against egg-propagated reference virus.

###### Antigenic analysis of virus isolates collected during the influenza season, Australia, 1 May--24 September 2017

  -------------------------------------------------------------------------------------------------------------------------------
  Influenza strain                Total viruses attempted^a^   Type of assay   Cell-propagated\   Egg-propagated\            
                                                                               reference strain   reference strain^b^        
  ------------------------------- ---------------------------- --------------- ------------------ --------------------- ---- ----
  A(H1)pdm09 A/Michigan/45/2015   55                           NA                                                            

  Positive                        48                           HAI             46                 0                     46   0

  Insufficient HA Titre for HAI   1                            NA                                                            

                                                                                                                             

  A(H3) A/Hong Kong/4801/2014     265                          NA                                                            

  Positive                        90                           HAI             60                 7                     45   22

  FRA                             31                           0               28                 3                          

  Insufficient HA Titre for HAI   98                           FRA             44                 0                     32   12

                                                                                                                             

  B/Victoria B/Brisbane/60/2008   7                            NA                                                            

  Positive                        6                            HAI             3                  1                     0    4

                                                                                                                             

  B/Yamagata B/Phuket/3073/2013   148                          NA                                                            

  Positive                        90                           HAI             52                 0                     50   2
  -------------------------------------------------------------------------------------------------------------------------------

FRA: focus reduction assay; HAI: haemagglutination inhibition assay. HA: haemagglutinin; NA: not applicable.

^a^ Virus isolation was not attempted for all viruses and not all isolates were analysed by HAI or FRA; FRA was only attempted for A(H3) viruses.

^b^ Results for post-infection ferret antisera raised to egg-propagated and cell-propagated reference viruses are presented because the egg-propagated reference viruses more closely resemble the vaccine strain, while cell-propagated reference viruses more closely resemble the original virus from which the vaccine strain was derived.

Sequences for the haemagglutinin gene were available for a subset of A(H3) viruses ([Figure 2](#f2){ref-type="fig"}). Examination of the phylogenetic tree identified considerable diversity with a number of viruses exhibiting amino acid substitutions in key glycosylation and antigenic sites but no specific clustering of vaccine failures. GISAID accession numbers for these viruses were 271246, 271303, 275219, 275220, 275225, 275226, 275227, 275228, 275246, 275247, 275248, 275278, 275280, 277305, 277315, 277557.

![Phylogenetic tree for the haemagglutinin gene of influenza A(H3) viruses](17-00707-f2){#f2}

Vaccines effectiveness estimates
================================

Vaccine effectiveness (VE) was estimated following a case--control test-negative design, where VE is estimated from the odds ratio (OR) comparing the odds of vaccination among test-positive and test-negative patients. The limitations of this design have been discussed at length \[[@r10],[@r11]\]. Estimates were adjusted for week of specimen collection (cubic spline with 4 knots), and age group (spline with knots at 5, 15, 35, 65, 75 years).

VE estimates are shown in [Table 2](#t2){ref-type="table"}. Overall VE was 33% (95%CI: 17 to 46). This estimate appeared to be skewed by the very low estimate for A(H3), which was 10% (95%CI: -16 to 31), whereas estimates were higher for A(H1)pdm09 (VE: 50%; 95%CI: 8 to 74) and B (VE: 57%; 95%CI: 41 to 69). VE for A(H3) 3C.2a viruses was 5% (95%CI: -51 to 40), while the estimate for 3C.2a1 was 19% (95%CI: -42 to 55). For patients vaccinated in the 2016 season, VE for A(H3) was 3--4% regardless of whether they were also vaccinated in 2017. In contrast, the highest VE point estimates for influenza B were observed among those vaccinated in both 2016 and 2017.

###### Interim sample characteristics and vaccine effectiveness estimates, Australia, 1 May 2017--24 September 2017

  Type/subtype                                       Age group   Cases   Controls   Adjusted^a^ VE (95% CI)                                               
  -------------------------------------------------- ----------- ------- ---------- ------------------------- ----- ----- ----- ----- ------------------- -----------------
  **A or B**                                         All ages    772     73%        288                       27%   802   63%   477   37%                 33% (17 to 46)
  Children \< 15y                                    235         94%     14         6%                        179   94%   12    6%    16% (-95 to 63)     
  Adults 15--64y                                     512         74%     181        26%                       587   65%   322   35%   39% (24 to 51)      
  Adults  ≥ 65y                                      25          21%     93         79%                       36    20%   143   80%   -3% (-92 to 44)     
  **A(H1)pdm09**                                     All ages    74      84%        14                        16%   802   63%   477   37%                 50% (8 to 74)
  Children \< 15y                                    33          97%     1          3%                        179   94%   12    6%    NE                  
  Adults 15--64y                                     40          78%     11         22%                       587   65%   322   35%   49% (2 to 76)       
  Adults ≥ 65y                                       1           33%     2          67%                       36    20%   143   80%   NE                  
  **A(H3)**                                          All ages    347     66%        175                       34%   802   63%   477   37%                 10% (-16 to 31)
  Children \< 15y                                    100         94%     6          6%                        179   94%   12    6%    17% (-132 to73)     
  Adults 15--64y                                     233         68%     110        32%                       587   65%   322   35%   16% (-11 to 36)     
  Adults ≥ 65y                                       14          19%     59         81%                       36    20%   143   80%   -20% (-160 to 42)   
  **A(H3) Clade 3C.2a**                              All ages    88      69%        40                        31%   802   63%   477   37%                 5% (-51 to 40)
  Children \< 15y                                    31          94%     2          6%                        179   94%   12    6%    NE                  
  Adults 15--64y                                     56          68%     26         32%                       587   65%   322   35%   14% (-40 to 49)     
  Adults ≥ 65y                                       1           8%      12         92%                       36    20%   143   80%   NE                  
  **A(H3) Clade 3C.2a1**                             All ages    52      67%        26                        33%   802   63%   477   37%                 19% (-42 to 55)
  Children \< 15y                                    14          93%     1          7%                        179   94%   12    6%    NE                  
  Adults 15--64y                                     37          76%     12         24%                       587   65%   322   35%   40% (-14 to 71)     
  Adults ≥ 65y                                       1           7%      13         93%                       36    20%   143   80%   NE                  
  **B**                                              All ages    306     82%        69                        18%   802   63%   477   37%                 57% (41 to 69)
  Children \< 15y                                    91          96%     4          4%                        179   94%   12    6%    NE                  
  Adults 15--64y                                     208         82%     45         18%                       587   65%   322   35%   63% (48 to 74)      
  Adults ≥ 65y                                       7           26%     20         74%                       36    20%   143   80%   10% (-156 to 65)    
  **B/Victoria**                                     All ages    11      100%       0                         0%    802   63%   477   37%                 NE
  Children \< 15y                                    4           100%    0          0%                        179   94%   12    6%    NE                  
  Adults 15--64y                                     7           100%    0          0%                        587   65%   322   35%   NE                  
  Adults ≥ 65y                                       0           NA      0          NA                        36    20%   143   80%   NE                  
  **B/Yamagata**                                     All ages    206     80%        53                        20%   802   63%   477   37%                 45% (22 to 62)
  Children \< 15y                                    71          96%     3          4%                        179   94%   12    6%    NE                  
  Adults 15--64y                                     130         77%     38         23%                       587   65%   322   35%   49% (26 to 66)      
  Adults ≥ 65y                                       5           29%     12         71%                       36    20%   143   80%   27% (-162 to 77)    
  **Repeated vaccination -- Influenza A(H1)pdm09**                                                                                                        
  Neither season                                     63          73%     NA         NA                        647   52%   NA    NA    Ref                 
  Both 2016 and 2017 seasons                         NA          NA      13         15%                       NA    NA    395   32%   NE                  
  2017 only                                          NA          NA      1          1%                        NA    NA    59    5%    NE                  
  2016 only                                          NA          NA      9          10%                       NA    NA    132   11%   NE                  
  **Repeated vaccination - Influenza A(H3)**                                                                                                              
  Neither season                                     294         17%     NA         NA                        647   52%   NA    NA    Ref                 
  Both 2016 and 2017 seasons                         NA          NA      155        30%                       NA    NA    395   32%   3% (-29 to 27)      
  2017 only                                          NA          NA      14         3%                        NA    NA    59    5%    43% (-1 to 71)      
  2016 only                                          NA          NA      47         9%                        NA    NA    132   11%   4% (-40 to 36)      
  **Repeated vaccination - Influenza B**                                                                                                                  
  Neither season                                     262         72%     NA         NA                        647   52%   NA    NA    Ref                 
  Both 2016 and 2017 seasons                         NA          NA      57         16%                       NA    NA    395   32%   59% (42 to 72)      
  2017 only                                          NA          NA      11         3%                        NA    NA    59    5%    50% (4 to 76)       
  2016 only                                          NA          NA      36         10%                       NA    NA    132   11%   22% (-18 to 47)     

CI: confidence interval; NA: not applicable; NE: not estimated (because cell counts are fewer than five); Ref: reference category VE: vaccine effectiveness; y: years.

Numbers are shown for all groups regardless of whether VE estimation was attempted. VE was only estimated where cell counts were at least five. Although presented, estimates for children and those aged ≥65 years typically have wide CIs and should be interpreted with caution. Note that the same control group is used for all comparisons within an age group.

^a^ All estimates adjusted for calendar time (cubic spline function with 4 knots). Estimates for all ages were also adjusted for age (cubic spline with knots at 5, 15, 35, 65, 75).

Discussion
==========

Our interim analysis suggests moderate VE against influenza A(H1)pdm09 and influenza B. However, VE was low against influenza A(H3). The antigenic data reflect ongoing issues with A(H3) candidate vaccine viruses which, when propagated in eggs, rapidly acquire adaptive changes in the haemagglutinin which alter antigenicity. Cell-based vaccines, which are less affected by this, are only licensed in the United States, were not available in Australia in 2017 and will also not be available for the upcoming European season. The significant genetic diversity of circulating viruses, many of which exhibit amino acid substitutions in key antigenic and glycosylation sites, also makes it difficult to select candidate vaccine viruses with high coverage.

This was the second season for which the A/Hong Kong/4801/2015-containing vaccine was used in Australia \[[@r3],[@r12]\], and campaigns currently underway in the northern hemisphere are also using it for a second time \[[@r5],[@r13]\]. During the 2016/17 northern hemisphere season interim VE estimates ranged from 15% (95%CI: --11 to 35) to 43% (95%CI: 29 to 54) \[[@r14]-[@r17]\]. It is unclear whether sequential vaccination will result in lower estimates for 2017/18, but our VE estimates were particularly low for people who received vaccine in 2016 and for older adults, 76% of whom were sequentially vaccinated. This finding is consistent with a modelling study which predicts low VE for sequentially vaccinated persons when the vaccine composition is identical, but the antigenic distance between the vaccine and circulating strains is high \[[@r18]\]. However, confounding due to prior infection status and negative interference from pre-2016 vaccines could not be controlled for in our analysis, and may have introduced bias.

In contrast to A(H3), VE estimates for influenza B were moderate and the combined effects of vaccination in 2016 and 2017 did not blunt effectiveness for influenza B, even though the composition remained the same. Similarly, VE for the few A(H1)pdm09 cases recruited was moderate, although low for Australia at 50% (95%CI: 8 to 74), where VEs have ranged from 54% to 79% in the past \[[@r6],[@r7]\]. This was the one component of the 2017 vaccine that was updated since 2016, from A/California/7/2009 to A/Michigan/45/2015.

This study provides interim estimates of the 2017 southern hemisphere influenza vaccine in the outpatient setting and may not apply to inpatient settings or severe illness. Interim estimates can reliably predict final season estimates \[[@r19]\], particularly when made after the peak \[[@r20]\], as is the case here. Should the circulating A(H3) influenza viruses predominate in the 2017/18 northern hemisphere influenza season \[[@r21]\], our results suggest that the vaccine may confer limited protection. Health authorities should consider other influenza prevention measures, including antivirals and health promotion messaging, in the event of a severe season and low VE against A(H3).
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